Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains

Kristen L. Sager, Joanne Wuu, Jeremy H. Herskowitz, Elliott J. Mufson, Allan I. Levey, James J. Lah

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Because the pathological changes underlying this disease can begin decades prior to the onset of cognitive impairment, identifying the earliest events in the AD pathological cascade has critical implications for both the diagnosis and treatment of this disease. We previously reported that compared to autopsy confirmed healthy control brain, expression of LR11 (or SorLA) is markedly reduced in AD brain as well as in a subset of people with mild cognitive impairment (MCI), a prodromal clinical stage of AD. Recent studies of the LR11 gene SORL1 have suggested that the association between SORL1 single nucleotide polymorphisms (SNPs) and AD risk may not be universal. Therefore, we sought to confirm our earlier findings in a population chosen solely based on clinical criteria, as in most genetic studies. Quantitative immunohistochemistry was used to measure LR11 expression in 43 cases from the Religious Orders Study that were chosen based on a final pre-mortem clinical diagnosis of MCI, mild/moderate AD or no cognitive impairment (NCI). LR11 expression was highly variable in all three diagnostic groups, with no significant group differences. Low LR11 cases were identified using the lowest tertile of LR11 expression observed across all cases as a threshold. Contrary to previous reports, low LR11 expression was found in only 29% of AD cases. A similar proportion of both the MCI and NCI cases also displayed low LR11 expression. AD-associated lesions were present in the majority of cases regardless of diagnostic group, although we found no association between LR11 levels and pathological variables. These findings suggest that the relationship between LR11 expression and the development of AD may be more complicated than originally believed.

Original languageEnglish
Article numbere40527
JournalPLoS One
Volume7
Issue number8
DOIs
StatePublished - Aug 21 2012

Fingerprint

Alzheimer disease
Brain
Alzheimer Disease
brain
Prodromal Symptoms
dementia
lesions (animal)
single nucleotide polymorphism
Single Nucleotide Polymorphism
immunohistochemistry
Dementia
Cognitive Dysfunction
Autopsy
necropsy
Polymorphism
Immunohistochemistry
Nucleotides
Genes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains. / Sager, Kristen L.; Wuu, Joanne; Herskowitz, Jeremy H.; Mufson, Elliott J.; Levey, Allan I.; Lah, James J.

In: PLoS One, Vol. 7, No. 8, e40527, 21.08.2012.

Research output: Contribution to journalArticle

Sager, Kristen L. ; Wuu, Joanne ; Herskowitz, Jeremy H. ; Mufson, Elliott J. ; Levey, Allan I. ; Lah, James J. / Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains. In: PLoS One. 2012 ; Vol. 7, No. 8.
@article{123d15fac5fa489285a5a816458d02af,
title = "Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains",
abstract = "Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Because the pathological changes underlying this disease can begin decades prior to the onset of cognitive impairment, identifying the earliest events in the AD pathological cascade has critical implications for both the diagnosis and treatment of this disease. We previously reported that compared to autopsy confirmed healthy control brain, expression of LR11 (or SorLA) is markedly reduced in AD brain as well as in a subset of people with mild cognitive impairment (MCI), a prodromal clinical stage of AD. Recent studies of the LR11 gene SORL1 have suggested that the association between SORL1 single nucleotide polymorphisms (SNPs) and AD risk may not be universal. Therefore, we sought to confirm our earlier findings in a population chosen solely based on clinical criteria, as in most genetic studies. Quantitative immunohistochemistry was used to measure LR11 expression in 43 cases from the Religious Orders Study that were chosen based on a final pre-mortem clinical diagnosis of MCI, mild/moderate AD or no cognitive impairment (NCI). LR11 expression was highly variable in all three diagnostic groups, with no significant group differences. Low LR11 cases were identified using the lowest tertile of LR11 expression observed across all cases as a threshold. Contrary to previous reports, low LR11 expression was found in only 29{\%} of AD cases. A similar proportion of both the MCI and NCI cases also displayed low LR11 expression. AD-associated lesions were present in the majority of cases regardless of diagnostic group, although we found no association between LR11 levels and pathological variables. These findings suggest that the relationship between LR11 expression and the development of AD may be more complicated than originally believed.",
author = "Sager, {Kristen L.} and Joanne Wuu and Herskowitz, {Jeremy H.} and Mufson, {Elliott J.} and Levey, {Allan I.} and Lah, {James J.}",
year = "2012",
month = "8",
day = "21",
doi = "10.1371/journal.pone.0040527",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains

AU - Sager, Kristen L.

AU - Wuu, Joanne

AU - Herskowitz, Jeremy H.

AU - Mufson, Elliott J.

AU - Levey, Allan I.

AU - Lah, James J.

PY - 2012/8/21

Y1 - 2012/8/21

N2 - Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Because the pathological changes underlying this disease can begin decades prior to the onset of cognitive impairment, identifying the earliest events in the AD pathological cascade has critical implications for both the diagnosis and treatment of this disease. We previously reported that compared to autopsy confirmed healthy control brain, expression of LR11 (or SorLA) is markedly reduced in AD brain as well as in a subset of people with mild cognitive impairment (MCI), a prodromal clinical stage of AD. Recent studies of the LR11 gene SORL1 have suggested that the association between SORL1 single nucleotide polymorphisms (SNPs) and AD risk may not be universal. Therefore, we sought to confirm our earlier findings in a population chosen solely based on clinical criteria, as in most genetic studies. Quantitative immunohistochemistry was used to measure LR11 expression in 43 cases from the Religious Orders Study that were chosen based on a final pre-mortem clinical diagnosis of MCI, mild/moderate AD or no cognitive impairment (NCI). LR11 expression was highly variable in all three diagnostic groups, with no significant group differences. Low LR11 cases were identified using the lowest tertile of LR11 expression observed across all cases as a threshold. Contrary to previous reports, low LR11 expression was found in only 29% of AD cases. A similar proportion of both the MCI and NCI cases also displayed low LR11 expression. AD-associated lesions were present in the majority of cases regardless of diagnostic group, although we found no association between LR11 levels and pathological variables. These findings suggest that the relationship between LR11 expression and the development of AD may be more complicated than originally believed.

AB - Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Because the pathological changes underlying this disease can begin decades prior to the onset of cognitive impairment, identifying the earliest events in the AD pathological cascade has critical implications for both the diagnosis and treatment of this disease. We previously reported that compared to autopsy confirmed healthy control brain, expression of LR11 (or SorLA) is markedly reduced in AD brain as well as in a subset of people with mild cognitive impairment (MCI), a prodromal clinical stage of AD. Recent studies of the LR11 gene SORL1 have suggested that the association between SORL1 single nucleotide polymorphisms (SNPs) and AD risk may not be universal. Therefore, we sought to confirm our earlier findings in a population chosen solely based on clinical criteria, as in most genetic studies. Quantitative immunohistochemistry was used to measure LR11 expression in 43 cases from the Religious Orders Study that were chosen based on a final pre-mortem clinical diagnosis of MCI, mild/moderate AD or no cognitive impairment (NCI). LR11 expression was highly variable in all three diagnostic groups, with no significant group differences. Low LR11 cases were identified using the lowest tertile of LR11 expression observed across all cases as a threshold. Contrary to previous reports, low LR11 expression was found in only 29% of AD cases. A similar proportion of both the MCI and NCI cases also displayed low LR11 expression. AD-associated lesions were present in the majority of cases regardless of diagnostic group, although we found no association between LR11 levels and pathological variables. These findings suggest that the relationship between LR11 expression and the development of AD may be more complicated than originally believed.

UR - http://www.scopus.com/inward/record.url?scp=84865154896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865154896&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0040527

DO - 10.1371/journal.pone.0040527

M3 - Article

C2 - 22927900

AN - SCOPUS:84865154896

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e40527

ER -